HK inno.N Corporation (KOSDAQ: 195940)

Market Cap	1.02T
Revenue (ttm)	839.63B
Net Income (ttm)	41.49B
Shares Out	28.33M
EPS (ttm)	1,451.65
PE Ratio	24.73
Forward PE	13.25
Dividend	350.00 (0.97%)
Ex-Dividend Date	n/a

Volume	129,293
Open	36,550
Previous Close	36,550
Day's Range	35,700 - 36,700
52-Week Range	34,300 - 52,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 12, 2025

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,695
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.